BioTuesdays

Tag - RVNC

Revance

Stifel starts Revance Therapeutics at buy; PT $50

Stifel initiated coverage of Revance Therapeutics (NASDAQ:RVNC) with a “buy” rating and $50 target price. The stock closed at $17 on Jan. 28. Revance’s Daxi product represents “one of the first truly novel neurotoxin...

Revance

Needham starts Revance Therapeutics at buy; PT $42

Needham initiated coverage of Revance Therapeutics (NASDAQ:RVNC) with a “buy” rating and $42 price target. The stock closed at $30.60 on March 26. Revance is involved in the development of novel and differentiated...